Matthew Sophy, DO
Adult Medicine · Port Carbon, PANPI 1922071620
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Lilly USA, LLC at 37.1% of the total. Reporting peaked in 2019 at $601 and has fallen 62.9% since, to $223 in 2025.
Across 114 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$795
- Amgen$414
- Novo Nordisk$333
- Amarin Pharma, Inc.$316
- Sunovion Pharmaceuticals Inc.$97
- AstraZeneca$91
- plus $99 from 5 others
What the payments were for
- Consulting fees$1758%
- Food & beverage$1,94991%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 46 | $795 |
| Amgen | 15 | $414 |
| Novo Nordisk | 21 | $333 |
| Amarin Pharma, Inc. | 14 | $316 |
| Sunovion Pharmaceuticals Inc. | 7 | $97 |
| AstraZeneca | 5 | $91 |
| Sumitomo Pharma America, Inc. | 2 | $47 |
| AbbVie | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| GSK | 1 | $13 |
| Irhythm Technologies, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,145 in reported general payments places this provider in the 80th percentile of 52 adult medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 93 | $114,826 |
| OzempicSemaglutide | 44 | $74,578 |
| TrulicityDulaglutide | 36 | $46,975 |
| Repatha SureclickEvolocumab | 24 | $25,907 |
| JardianceEmpagliflozin | 14 | $22,790 |
| FarxigaDapagliflozin Propanediol | 16 | $21,743 |
| TradjentaLinagliptin | 13 | $18,487 |
| JanuviaSitagliptin Phosphate | 13 | $10,443 |
| XareltoRivaroxaban | 13 | $10,147 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $9,825 |
| LinzessLinaclotide | 17 | $8,923 |
| Rosuvastatin Calcium | 326 | $5,922 |
| Ezetimibe | 115 | $3,738 |
| Atorvastatin Calcium | 304 | $3,591 |
| Lisinopril | 330 | $2,880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $333 | $74,57844 claims |
| Lilly USA, LLCTrulicity | $795 | $46,97536 claims |
| AstraZenecaFarxiga | $91 | $21,74316 claims |
| AbbVieLinzess, Synthroid | $14 | $10,29249 claims |
| GSKTrelegy Ellipta | $13 | $9,82513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 52 adult medicine providers in Pennsylvania.
Other adult medicine in Port Carbon
- Peter HonigPhiladelphia$140K
- Mark WatkinsPhiladelphia$54K
- Emily ScaruzziPhiladelphia$16K
- Harvey SpectorPhiladelphia$15K
- Gina SloboginUpper Chichester$15K
- Larry HahnTrevose$8K
- Gregory GeorgeSharon$7K
- Victoria KorkusPhoenixville$4K
- Jay RobinsonCoalport$3K
- Matthew KulkaLanghorne$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.